Results 151 to 160 of about 24,145,261 (292)

Structural themes of cereblon‐recruiting degraders: selected recent examples

open access: yesActa Crystallographica Section F, EarlyView.
Structural studies of cereblon‐recruiting degrader complexes have transformed our understanding of targeted protein degradation. This review discusses selected examples of how X‐ray crystallography and cryogenic‐electron microscopy have enabled the structure‐guided optimization of heterobifunctional degraders and molecular‐glue degraders.
Sana Ahmed, Michael Rowley
wiley   +1 more source

Is retinal vein occlusion an underrecognized paraneoplastic sentinel of lymphoma? A systematic review and meta‐analysis of ocular–haematological interactions

open access: yesActa Ophthalmologica, EarlyView.
Abstract Topic This systematic review and meta‐analysis evaluated the association between retinal vein occlusion (RVO) and lymphoma across two complementary evidence components: a qualitative clinical synthesis of RVO occurring in patients with lymphoma and a quantitative synthesis of subsequent cancer outcomes in patients with RVO. For the qualitative
Kai‐Yang Chen   +2 more
wiley   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest   +15 more
wiley   +1 more source

Diffuse Large B-cell Lymphoma of the Testis [PDF]

open access: yesMayo Clinic Proceedings, 2016
Rosalind F, Sandell, Lori A, Erickson
openaire   +2 more sources

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

open access: yesBritish Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy